Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $12.69, up 2.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AMLX shares have gain 3.09% over the last week, with a monthly amount drifted -16.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on June 24, 2025, and set its price target to $17. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $12 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Mizuho upgraded its rating to a Outperform but $7 remained the price target by the analyst firm on April 07, 2025. Robert W. Baird upgraded its rating to Outperform for this stock on November 18, 2024, and upped its price target to $11. In a note dated October 23, 2024, BofA Securities upgraded an Buy rating on this stock and boosted its target price from $4.20 to $10.
Amylyx Pharmaceuticals Inc [AMLX] stock has fluctuated between $2.60 and $16.96 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $12.69 at the most recent close of the market. An investor can expect a potential return of 57.6% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] reported sales of -0.67M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.45% with Operating Profit Margin at 236.6%, Pretax Profit Margin comes in at 225.44%, and Net Profit Margin reading is 224.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.69 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.29 points at the first support level, and at 11.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.94, and for the 2nd resistance point, it is at 13.20.
Ratios To Look Out For
For context, Amylyx Pharmaceuticals Inc’s Current Ratio is 13.70. Further, the Quick Ratio stands at 13.70, while the Cash Ratio is 8.73.
Transactions by insiders
Recent insider trading involved Klee Justin B., Co-Chief Executive Officer, that happened on Sep 30 ’25 when 29975.0 shares were sold. Chief Legal Officer, Mazzariello Gina completed a deal on Sep 30 ’25 to sell 8828.0 shares. Meanwhile, Chief Financial Officer FRATES JAMES M sold 10558.0 shares on Sep 30 ’25.
